Search Results - "Loos, WJ"

Pharmacological effects of formulation vehicles: Implications for cancer chemotherapy by TEN TIJE, Albert J, VERWEIJ, Jaap, LOOS, Walter J, SPARREBOOM, Alex

“…The non-ionic surfactants Cremophor EL (CrEL; polyoxyethyleneglycerol triricinoleate 35) and polysorbate 80 (Tween) 80; polyoxyethylene-sorbitan-20-monooleate)…”
Get full text

Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2) by Burger, H, Zoumaro‐Djayoon, A, Boersma, AWM, Helleman, J, Berns, EMJJ, Mathijssen, RHJ, Loos, WJ, Wiemer, EAC

“…Background:  Solute carriers (SLCs), in particular organic cation transporters (OCTs), have been implicated in the cellular uptake of platinum‐containing…”
Get full text

A Long-term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients by EECHOUTE, Karel, FRANSSON, Martin N, LOOS, Walter J, MATHIJSSEN, Ron H. J, DE GIORGI, Ugo, REYNERS, An K, DE JONG, Floris A, SPARREBOOML, Alex, VAN DER GRAAF, Winette T. A, FRIBERG, Lena E, SCHIAVON, Gaia, WIEMER, Erik A. C, VERWEIJ, Jaap

“…Imatinib minimal (trough) plasma concentrations after one month of treatment have shown a significant association with clinical benefit in patients with…”
Get full text

Effects of St. John's Wort on Irinotecan Metabolism by Mathijssen, Ron H. J., Verweij, Jaap, de Bruijn, Peter, Loos, Walter J., Sparreboom, Alex

“…St. John's wort (SJW), a widely used herbal product, has been implicated in drug interactions resulting from the induced expression of the cytochrome P450…”
Get full text

Clinical Pharmacokinetics and Metabolism of Irinotecan (CPT-11) by MATHIJSSEN, Ron H. J, VAN ALPHEN, Robbert J, VERWEIJ, Jaap, LOOS, Walter J, NOOTER, Kees, STOTER, Gerrit, SPARREBOOM, Alex

“…CPT-11 belongs to the class of topoisomerase I inhibitors, and it acts as a prodrug of SN-38, which is approximately 100–1000-fold more cytotoxic than the…”
Get full text

Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 Polymorphisms with the Pharmacokinetics of Paclitaxel by Henningsson, Anja, Marsh, Sharon, Loos, Walter J, Karlsson, Mats O, Garsa, Adam, Mross, Klaus, Mielke, Stephan, Viganò, Lucia, Locatelli, Alberta, Verweij, Jaap, Sparreboom, Alex, McLeod, Howard L

“…Purpose: To retrospectively evaluate the effects of six known allelic variants in the CYP2C8, CYP3A4, CYP3A5 , and ABCB1 genes on the pharmacokinetics of the…”
Get full text

Effect of ABCG2 genotype on the oral bioavailability of topotecan by Sparreboom, Alex, Loos, Walter J, Burger, Herman, Sissung, Tristan M, Verweij, Jaap, Figg, William D, Nooter, Kees, Gelderblom, Hans

“…ABCG2 (BCRP/MXR/ABCP) functions as an efflux transporter for many agents, including topotecan, and the protein is expressed at high levels in the human…”
Get full text

Environmental and Genetic Factors Affecting Transport of Imatinib by OATP1A2 by Eechoute, K, Franke, RM, Loos, WJ, Scherkenbach, LA, Boere, I, Verweij, J, Gurney, H, Kim, RB, Tirona, RG, Mathijssen, RHJ, Sparreboom, A

“…The bioavailability of orally administered imatinib is >90%, although the drug is monocationic under the acidic conditions in the duodenum. In vitro, we found…”
Get full text

Association of ABCC2 polymorphisms with cisplatin disposition and efficacy by Sprowl, JA, Gregorc, V, Lazzari, C, Mathijssen, RH, Loos, WJ, Sparreboom, A

“…ABCC2 (MRP2; cMOAT) expression has been implicated in cisplatin resistance in vitro . In mice, cisplatin disposition and toxicity were unaffected by Abcc2…”
Get full text

Cremophor EL-mediated alteration of paclitaxel distribution in human blood : Clinical pharmacokinetic implications by SPARREBOOM, A, VAN ZUYLEN, L, BROUWER, E, LOOS, W. J, DE BRUIJN, P, GELDERBLOM, H, PILLAY, M, NOOTER, K, STOTER, G, VERWEIJ, J

“…We have determined the in vitro and in vivo cellular distribution of the antineoplastic agent paclitaxel (Taxol) in human blood and the influence of Cremophor…”
Get full text

Effect of Cytochrome P450 3A4 Inhibition on the Pharmacokinetics of Docetaxel by Engels, Frederike K., Tije, Albert J., Baker, Sharyn D., Lee, Carlton K. K., Loos, Walter J., Vulto, Arnold G., Verweij, Jaap, Sparreboom, Alex

“…Objective In vitro studies indicate that the anticancer drug docetaxel is primarily eliminated by cytochrome P450 (CYP) 3A4–mediated metabolism…”
Get full text

Clinical pharmacokinetics of unbound docetaxel: Role of polysorbate 80 and serum proteins by Loos, Walter J., Baker, Sharyn D., Verweij, Jaap, Boonstra, Joke G., Sparreboom, Alex

“…Objective Our objectives were to study the extent of docetaxel binding to plasma in the presence and absence of its excipient, polysorbate 80 (Tween 80;…”
Get full text

P2-17-04: Induction of Tamoxifen Metabolism by Rifampicin: A Worrying Drug-Drug Interaction by Binkhorst, L, Loos, WJ, de, Jongh FE, Hamberg, P, Ghobadi, Moghaddam-Helmantel IM, Jager, A, Seynaeve, C, Verweij, J, van, Gelder T, Mathijssen, RH

“…Abstract Background Tamoxifen (Tam) undergoes extensive biotransformation into several metabolites, including the highly active metabolite endoxifen…”
Get full text

Effect of omeprazole on the pharmacokinetics and toxicities of irinotecan in cancer patients: A prospective cross-over drug–drug interaction study by van der Bol, Jessica M, Loos, Walter J, de Jong, Floris A, van Meerten, Esther, Konings, Inge R.H.M, Lam, Mei H, de Bruijn, Peter, Wiemer, Erik A.C, Verweij, Jaap, Mathijssen, Ron H.J

“…Abstract Background Omeprazole is one of the most prescribed medications worldwide and within the class of proton pump inhibitors, it is most frequently…”
Get full text

Correlation between imatinib trough levels and clinical benefit in gastrointestinal stromal tumors (GIST): Results of a prospective population pharmacokinetic study by Eechoute, K., Fransson, M. N., De Giorgi, U., Reyners, A. K. L., de Jong, F. A., Friberg, L. E., Van Der Graaf, W. T., Sparreboom, A., Verweij, J., Loos, W. J., Mathijssen, R.

“…Abstract only…”
Get full text

Body-Surface Area–Based Dosing Does Not Increase Accuracy of Predicting Cisplatin Exposure by DE JONGH, Felix E, VERWEIJ, Jaap, LOOS, Walter J, DE WIT, Ronald, DE JONGE, Maja J. A, PLANTING, André S. T, NOOTER, Kees, STOTER, Gerrit, SPARREBOOM, Alex

“…Most anticancer drugs are dosed based on body-surface area (BSA) to reduce interindividual variability of drug effects. We evaluated the relevance of this…”
Get full text

Elongated Multiple Electronic Cascade and Cyclization Spacer Systems in Activatible Anticancer Prodrugs for Enhanced Drug Release by de Groot, Franciscus M. H, Loos, Walter J, Koekkoek, Ralph, van Berkom, Leon W. A, Busscher, Guuske F, Seelen, Antoinette E, Albrecht, Carsten, de Bruijn, Peter, Scheeren, Hans W

“…The design and synthesis of several novel elongated self-elimination spacer systems for application in prodrugs is described. These elongated spacer systems…”
Get full text

Measurement of Fraction Unbound Paclitaxel in Human Plasma by BROUWER, Eric, VERWEIJ, Jaap, DE BRUIJN, Peter, LOOS, Walter J, PILLAY, Marrimuthoo, BUIJS, Dirk, SPARREBOOM, Alex

“…The clinical pharmacokinetic behavior of paclitaxel (Taxol) is distinctly nonlinear, with disproportional increases in systemic exposure with an increase in…”
Get full text

Evaluation of an Alternate Dosing Strategy for Cisplatin in Patients With Extreme Body Surface Area Values by LOOS, Walter J, DE JONGH, Felix E, SPARREBOOM, Alex, DE WIT, Ronald, VAN BOVEN-VAN ZOMEREN, Desiree M, STOTER, Gerrit, NOOTER, Kees, VERWEIJ, Jaap

“…The majority of cytotoxic drugs for adults are dosed based on body surface area (BSA), aiming to reduce interpatient variability in drug exposure. We…”
Get full text

Mechanism-based models for topotecan-induced neutropenia by Léger, Frédéric, Loos, Walter J., Bugat, Roland, Mathijssen, Ron H. J., Goffinet, Marine, Verweij, Jaap, Sparreboom, Alex, Chatelut, Etienne

“…Objective A semiphysiologic pharmacokinetic‐pharmacodynamic model was applied to describe topotecan‐induced neutropenia, to quantify interindividual and…”
Get full text